Screener
Celldex Therapeutics CLDX Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from Celldex Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
FAQ
- What is Celldex Therapeutics's current ratio?
- Celldex Therapeutics (CLDX) reported current ratio of 11.8× in Q2 2026.
- How has Celldex Therapeutics's current ratio changed year-over-year?
- Celldex Therapeutics's current ratio decreased by 39.9% year-over-year, from 19.7× to 11.8×.
- What is the long-term trend for Celldex Therapeutics's current ratio?
- Over 5 years (2020 to 2025), Celldex Therapeutics's current ratio has grown at a -5.5% compound annual growth rate (CAGR), from 13.9× to 10.5×.
- What does current ratio mean?
- Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.
Ask your AI about Celldex Therapeutics's current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude